Oncolytic virotherapy has been shown to be clinically effective when delivered by intra‐tumoural injection.10 However, the systemic administration of oncolytic virotherapy is hampered by sequestration within the reticulo‐endothelial system, clearance by circulating antibodies and an inability to penetrate the tumour in sufficient titres.11 Due to its ability to target the delivery of therapy directly to the tumour whilst affording protection from viral sequestration, ILP was thought to be ideally suited to combination with oncolytic virotherapy. This evidence concerns the gene XIAP and neoplasm.